Xeris Biopharma (NASDAQ:XERS) Insider Sells $127,350.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total transaction of $127,350.00. Following the transaction, the insider directly owned 1,639,208 shares of the company’s stock, valued at approximately $13,916,875.92. This trade represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, August 3rd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.02, for a total value of $120,300.00.
• On Wednesday, July 1st, Kevin McCulloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total value of $722,700.00.

Xeris Biopharma Stock Up 0.1%

Shares of NASDAQ:XERS opened at $8.59 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The company has a market capitalization of $1.57 billion, a P/E ratio of -78.09 and a beta of 0.70. Xeris Biopharma Holdings, Inc. has a 52-week low of $5.25 and a 52-week high of $10.08. The stock’s fifty day simple moving average is $8.39 and its 200-day simple moving average is $6.97.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. As a group, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently bought and sold shares of the stock. Walleye Capital LLC acquired a new position in Xeris Biopharma in the second quarter valued at $4,841,000. Rice Hall James & Associates LLC purchased a new position in shares of Xeris Biopharma in the 1st quarter worth about $1,456,000. Janus Henderson Group PLC lifted its stake in shares of Xeris Biopharma by 322.8% in the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock valued at $1,713,000 after purchasing an additional 225,602 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Xeris Biopharma in the 2nd quarter valued at about $1,007,000. Finally, Granahan Investment Management LLC grew its holdings in shares of Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after purchasing an additional 873,236 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on XERS. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Barclays increased their price target on Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.00.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.